Kornimate/medical-research-clean huggingface dataset:
multicenter continuous peripheral nerve block surveillance study

Conditions: Postoperative Pain

Summary: this two tiered study is a multi-center, open label, surveillance study of the use of continuous nerve blocks with the on-q® c-bloc and either nerve stimulator or ultrasound guided continuous nerve block techniques. this study was developed to investigate specific aspects of complication rates related to continuous nerve block techniques in patients undergoing orthopedic surgical procedures.

continuous peripheral nerve block techniques require the placement of catheters near target peripheral nerves. the placement of these catheters is guided by either ultrasound visualization, nerve stimulation or a combination of the two. this surveillance study was designed to look at the rates of catheter placement related complications with the two techniques.

Eligibility criteria:
inclusion criteria: * patients having elective orthopedic surgery who are candidates for cpnb as part of their management program for postoperative pain * age \>18 * able to give consent exclusion criteria: * morbid obesity (bmi\> 40) * uncooperative or having psychological or linguistic difficulties * previous damage to the nerve or plexus * significant comorbidities which the primary investigator feels would limit the quality and collection of data * allergy to local anesthetic agents including ropivacaine, bupivacaine and lidocaine

Keywords: ultrasonography peripheral nerve block peripheral nerve stimulation
impact of yoga as complementary therapy in patients undergoing radical prostatectomy

Conditions: Prostate Cancer

Summary: the researchers hope to learn if yoga complementary therapy would improve health-related quality of life, recovery of urinary continence and erectile function in patients who underwent prostate cancer surgery (i.e. radical prostatectomy). we hypothesized that in patients undergoing radical prostatectomy, preoperative and postoperative yoga complementary therapy would improve health- related quality of life (hrqol), recovery of urinary continence and erectile function. this two-arm, randomized controlled pilot study will compare yoga intervention to usual care group. the aim is to evaluate the efficacy of yoga complementary therapy on hrqol in patients who underwent radical prostatectomy (rp). yoga therapy will be given to the intervention group three times in a week for 6 weeks prior to surgery and then initiated 3 weeks after the surgery for another 6 weeks. the yoga exercise will be tailored to the participant's comfort level. as an exploratory analysis, we will evaluate pro-inflammatory and immunological markers.


Eligibility criteria:
inclusion criteria: * men between the age of 30 to 80 * has been diagnosed with localized prostate cancer (i.e. pathologically and/or radiographically confirmed) * is scheduled to undergo radical prostatectomy (i.e. robot-assisted or open-approach) * has no other active primary malignancy aside from prostate cancer * currently not practicing yoga as a form of exercise and/or meditation * does not have uncontrolled pain * does not have neurological or musculoskeletal co-morbidity inhibiting exercise * has never been diagnosed by health care professionals to have absolute contraindications to exercise testing * willing to be randomized to either standard care or intervention group * willing to participate in yoga therapy for twelve weeks if randomized to intervention group * willing to undergo phlebotomy * able and willing to provide informed consent exclusion criteria: * men under the age of 30 or over the age of 80 * has not been diagnosed with localized prostate cancer (i.e. pathologically and/or radiographically confirmed) * is not scheduled to undergo radical prostatectomy (i.e. robot-assisted or open-approach) * has other active primary malignancy aside from prostate cancer * currently practicing yoga as a form of exercise and/or meditation * has uncontrolled pain * has neurological or musculoskeletal co-morbidity inhibiting exercise * has been diagnosed with psychotic, addictive, and major cognitive disorders * has been diagnosed by health care professionals to have absolute contraindications to exercise testing unwilling to be randomized to either standard care or intervention group * unwilling to participate in yoga therapy for twelve weeks if randomized to intervention group * unwilling to undergo phlebotomy * unable and unwilling to provide informed consent

Keywords: prostatectomy yoga therapy health related quality of life
magnetically controlled capsule endoscopy in visualization of the ugi and small intestine

Conditions: Stomach Diseases; Small Intestine Disease

Summary: in this study, we retrospectively analyzed the videos of combined upper digestive tract and small intestine examination under mce, so as to clarify the feasibility and diagnostic efficacy of mce in one-time examination of the upper gastrointestinal and small intestinal mucosa.

magnetically controlled capsule endoscopy (mce), with equally favorable diagnostic accuracy as conventional endoscopy, has become a painless noninvasive diagnostic modality in clinical practice. the more than 8 hours battery life of the mce enables a further examination of the small bowel. in addition, it has been demonstrated that magnetic steering of capsule endoscopy improves the completion rate of small bowel examination by facilitating passage of the capsule through the pylorus, which further supported mce as a practical modality for examination of both the stomach and small bowel. in this study, we retrospectively analyzed the videos of combined upper digestive tract and small intestine examination under mce, so as to clarify the feasibility and diagnostic efficacy of mce in one-time examination of the upper gastrointestinal and small intestinal mucosa.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old. 2. those who underwent upper gastrointestinal and small intestinal mucosal examination under magnetically controlled capsule endoscopy at shanghai changhai hospital and chinese pla general hospital after january 2020. 3. able to provide informed consent. exclusion criteria: 1. patients who fail to follow the prescribed procedures for magnetically controlled capsule endoscopy; 2. patients who only undergo gastric examination under magnetically controlled capsule endoscopy; 3. patients who only undergo small bowel examination under magnetic control capsule endoscopy; 4. the patient's basic information in the database is incomplete； 5. patient fail to be followed up.

Keywords: capsule endoscopy
open-label, randomised parallel-group study

Conditions: Prostate Cancer

Summary: an open-label, multi-centre, randomised parallel-group study, investigating efficacy and safety of different degarelix three-month dosing regimens in patients with prostate cancer requiring androgen ablation therapy.


Eligibility criteria:
inclusion criteria: * patients, aged 18 years or older, with a histologically proven prostate cancer of all stages in whom endocrine treatment is indicated. * screening testosterone level above the lower limit of normal range, globally defined as \> 2.2 ng/ml. * screening psa level of =2 ng/ml. ecog score of =2. * life expectancy of at least one year. criteria for evaluation: primary endpoint: * probability of testosterone at castrate level (=0.5 ng/ml) from day 28 through day 364. secondary endpoints: * probability of testosterone at castrate level (=0.5 ng/ml) from day 56 through day 364. * serum levels of testosterone, lh, fsh, and psa over time. * time to psa failure - defined as two consecutive increases of 50%, and at least 5 ng/ml, compared to nadir. * plasma levels of degarelix over time. * frequency and severity of adverse events. * clinically significant changes in laboratory safety parameters. * clinically significant changes in physical examinations, ecgs, vital signs, and body weight.

Keywords: prostate cancer requiring androgen ablation therapy
tirofiban for patients treated with alteplase

Conditions: Ischemic Stroke

Summary: after intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. in the mr tea, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone.


Eligibility criteria:
inclusion criteria: * age ≥18 * ischemic stroke symptom with onset ≤4.5 hours treated with iv rt-pa according with local guidelines. * 6≤ nihss ≤20 before iv tpa, or nihss \>20 but decrease ≥ 8 after iv rt-pa. * ≥ 4 point total nihss or ≥ 2 point in one nihss category during and after the iv rt-pa compared to immediately before worsening, an emergency ct scan should be performed to exclude intracranial hemorrhage * patients or their legally acceptable representative agreed to the treatment and signed the informed consent form exclusion criteria: * patients whom the treating physician is planning to treat with mechanical thrombectomy or other endovascular procedure (e.g. intra-arterial thrombolysis) according with local guidelines. * patients had used antiplatelet therapy in the past 5 days before the stroke. * patients had used anticoagulant therapy in the past 5 days before the stroke. * scheduled for surgery or interventional treatment requiring study drug cessation. * ct scan finding of hypoattenuation involving ≥1/3 of the mca territory. * any evidence of clinically significant bleeding ,or known coagulopathy. * renal insufficiency (creatinine clearance rate \<30ml/min) * hepatic dysfunction (alt \>2 folds of upper limit of normal value or ast\>2 folds of upper limit of normal value). * pre-existing disability with ≥ mrs 2. * known allergic to tirofiban or other glycoprotein iib/iiia antagonist. * severe non-cerebrovascular disease with life expectancy \<3 months
use of a novel diet (uc diet) for treatment of mild to moderate active pediatric ulcerative colitis

Conditions: Ulcerative Colitis (UC)

Summary: the goal of the study is to evaluate strategies that target the microbiota for the treatment of ulcerative colitis , this study will involve a novel diet that the investigators developed , based on the hypothesis that uc involves dysbiosis , underutilzation of certain metabolic pathways and use of pathways that increase risk of inflammation . the investigators have postulated that manipulation of colonic bacterial metabolism with this diet will induce remission in uc without involving additional immune suppression.

ulcerative colitis is a chronic inflammatory disease primarily involving the colon. it has long been considered to be due to a dysregulated immune response targeting the colon, and involves unknown environmental factors . recent studies have highlighted several characteristics which may suggest that uc is associated with alterations of the microbiota, defective production of short chain fatty acids and an impaired mucous layer. however at present, no effective therapy targets the microbiota or its interaction with the colonic epithelium. uc in humans is characterized by increased mucosal sulfides and increased sulfate and sulfide reducing bacteria and activation of amino acid metabolism pathways which impair butyrate production, whereas certain dietary patterns in humans and rodent models may induce dysbiosis and favor sulphide reducing bacteria. further support for targeting the microbiota includes several studies demonstrating that antibiotics might be helpful for severe refractory colitis. development of treatment strategies that target the microbiota could reduce exposure to immune suppression, and add new therapeutic strategies that do not exist at present. though diet has a significant impact on the composition of the microbiota no dietary intervention to date has proven effective for induction of remission. the investigators hypothesized that ulcerative colitis is caused by a series of events involving dysbiosis with sulfate or sulfide reducing bacteria combined with defective production of short chain fatty acids, coupled with a defective mucous layer.

Eligibility criteria:
inclusion criteria: 1. informed consent 2. established diagnosis of uc. 3. age: 8 - 19 years ( inclusive) 4. mild to moderate active disease, 10 ≤ pucai ≤45. 5. stable medication (imm/ 5asa) use for the past 6 weeks. patients who have received topical 5asa therapy for \<7 days and are active may be included if topical therapy is stopped at enrolment exclusion criteria: exclusion criteria: 1. any proven current infection such as positive stool culture, parasite or c. difficile. 2. antibiotic or steroids use in the past 2 weeks. 3. pucai \>45 4. acute severe uc in the previous 12 months. 5. current extra intestinal manifestation of uc. 6. psc or liver disease 7. pregnancy. 8. allergy to one of the antibiotics or age \<11 will exclude patients from entering the antibiotic arm
circadian variations of prostaglandin in sleep apnea

Conditions: Sleep Apnea; Continuous Positive Airway Pressure; Prostaglandins; Circadian Variations

Summary: the purpose of this study is to evaluate the associations of circadian variations, sleep architecture, hypertension and prostanoids in the patients with sleep apnea. in addition, the patients introduced to continuous positive airway pressure(cpap) treatment, the effects of cpap are also evaluated.

obstructive sleep apnea (osa) is characterized by repetitive episodes of upper airway obstruction during sleep that provoke frequents arousals, sleep fragmentation, oxygen desaturation, and excessive daytime sleepiness. osa may contribute to the development of systemic hypertension, cardiovascular disease. many studies has reported a crucial role for the prostaglandin d system in sleep regulation. in addition, it has been described urinary or blood levels of prostaglandins was higher in the patients with hypertension, diabetes mellitus, and these values were associated with the severity of coronary artery disease. however, the relation between alterations of prostaglandin d system and sleep architecture, sleepiness, and clinical outcomes such as hypertension, arteriosclerosis in the patients with osa are not known. additionally, after cpap treatment, we will investigate the association between change of prostaglandin system and sleep architecture, sleepiness, clinical outcomes.

Eligibility criteria:
inclusion criteria: * subjects on admission for sleep study under the respiratory care and sleep control medicine, kyoto university hospital. * subjects diagnosed with osa (apnea hypopnea index \>=5/hour) by overnight polysomnography. exclusion criteria: * subjects treating for acute infections or malignancy. * subjects with severe cardiovascular disease, diabetes,and renal failure. * subjects taking nonsteroidal anti-inflammatory drugs, steroids or immunosuppressants.

Keywords: sleep apnea cpap prostaglandins circadian variations
semi-automatic response system(sars)in type 2 diabetes

Conditions: Diabetes Mellitus

Summary: background * various kinds of interactive online communication systems have been introduced for long-term diabetes management, and their importance in managing patients is increasing. the investigators investigated the amount of physician time needed to maintain such a system, and the investigators developed software to maximise the cost effectiveness. methods * the investigators conducted a prospective, randomised, controlled trial to investigate the efficacy and safety of a semi-automatic response system (sars) for online glucose monitoring over a 24-week period of patients with type 2 diabetes. in the sars group, the "sars" software filtered the recorded self-monitoring of blood glucose data automatically to reduce the physicians' time, and the physicians managed patients regularly but only manually in the control (manual) group. the investigators measured the time spent by the physicians for online management and compared the hba1c levels at enrolment and follow-up.


Eligibility criteria:
inclusion criteria: * men or women aged 20-70 years with type 2 diabetes * lasting more than one year who had used the online communication system for diabetes management at the web site https://www.bi odang.com for more than six months * baseline hba1c level was 6-10% * patients who able and willing to complete glucose-monitoring diaries on a web chart as instructed. exclusion criteria: * patients who required intensive insulin therapy (multiple insulin injections or insulin pump therapy) or who were unwilling to use self-monitoring of blood glucose (smbg) * acute metabolic complications of diabetes (e.g., diabetic ketoacidosis, hyperosmolar non-ketotic hyperglycaemia, lactic acidosis) * serum creatinine concentration \>2.0 mg/dl at screening * active liver disease or alt or ast activities \>2.5 times the upper limit of normal * acute illness, chronic infection, heart failure of nyha class iii or iv * recent myocardial infarction or stroke during the past six months * pregnancy or gdm, or any other factor likely to limit protocol compliance or reporting of adverse events

Keywords: semi-automatic response system (sars) diabetes mellitus internet ubiquitous health care system
no drop post-op cataract surgery

Conditions: Cataract

Summary: this study evaluates the effect of intraocular phenylephrine/ketorolac infusion on retinal thickness and macular edema in cataract surgery. participants will receive infusions of phenylephrine/ketorolac during surgery instead of receiving topical nsaid drops pre and post operatively.

topical nsaids have been known to reduce post-operative macular edema, inflammation and pain in patients undergoing cataract surgery. routine cataract surgery without the protection of topical nsaids results in an increase of the number of patients with macular edema and macular thickening. omidria (phenylephrine and ketorolac injection 1%/0.3%) infusion is used in patients during cataract surgery to decrease post-operative pain and inflammation. it is also indicated to maintain pupil dilation during cataract surgery. this study will evaluate whether treating patients with omidria during cataract surgery will control post-operative pain and inflammation as well as reduce or eliminate macular edema without the use of adjunctive topical nsaids.

Eligibility criteria:
inclusion criteria: * adults age 55-90 years with visual significant cataracts in one or both eyes. * healthy individuals able to tolerate outpatient cataract surgery under local anesthesia via either phacoemulsification and/or femtosecond assisted cataract surgery. well-controlled diabetes, hypertension will be included. * females of childbearing potential must agree to use a reliable method of birth control while participating in this study. reliable methods of birth control are: abstinence, oral contraceptives, intrauterine device (iud), depoprovera, tubal ligation or vasectomy of the partner (with confirmed negative sperm counts) in monogamous relationship (same partner). an acceptable, although less reliable, method involves the careful use of condoms and spermicidal foam or gel and/or cervical cap or sponge. a pregnancy test is required at least 10 days from the last normal menstrual period, if the patient is a sexually active female of childbearing potential. exclusion criteria: * allergy to phenylephrine or nsaids. * inability to sit steady and upright for the optical coherence tomography (oct). * complications during surgery, including posterior capsular rupture, vitreous loss, zonular dialysis, or iris trauma. * macular thickness above 300 microns at baseline * currently taking a prostaglandin analogue * presence of an epiretinal membrane on the preoperative oct. * retained lens fragment post-operatively. * inability to return for follow appointments * female patients who are pregnant, lactating or planning to become pregnant during the course of treatment.
natural history of sma

Conditions: Muscular Atrophy, Spinal

Summary: this is an investigator initiated observational study with the aim to record several aspects of function, care and adverse events in a large cohort of sma patients followed longitudinally by using a structured academic disease registry.

this is an observational multicenter retrospective and prospective study involving high quality data collected in 5 academic centers in italy, the registry aims to * better understand the natural history of the disease in untreated patients identifying factors that can influence disease progression by combining retrospective and prospective data. * describe the patterns of disease progression (in terms of functional measure, adverse events, levels of care, and hospitalization) in treated and untreated patients * identify all the patients treated with the available therapies in italy, providing first line details on epidemiological data in a wider network including all centers recognized as centers for spinal muscular atrophy (sma) in each region. as part of the activity clinical evaluators, data manager and sub-investigators are also trained and use common manuals of operation to ensure reliability across the participating centers. the registry provides accurate and reliable information on natural history including results from currently used functional measures. the registry also includes information on supportive care, hospitalization and adverse events. details of the electronic clinical file record including data assembly and the platform used are available as part of a peer reviewed paper

Eligibility criteria:
inclusion criteria: all patients exclusion criteria: if enrolled in clinical trials

Keywords: natural history spinal muscular atrophy
stavanger ibd study - cross sectional

Conditions: Inflammatory Bowel Disease

Summary: in this cross sectional and longitudinal study, patients with inflammatory bowel disease on biological treatment with infliximab or adalimumab will be included. after inclusion, the dosage of their existing biological therapy will be adjusted following regular trough-level and antibody-level monitoring, according to a treatment algorithm. disease activity markers, fatigue and qol will be assessed during the study. the hypothesis is that therapeutic drug monitoring may improve clinical disease outcome after one year of follow-up.


Eligibility criteria:
inclusion criteria: * patients diagnosed with inflammatory bowel disease on treatment with infliximab or adalimumab of any duration (at least 3 doses) exclusion criteria: * inability to consent * inability to adhere to treatment protocol.

Keywords: therapeutic drug monitoring biological treatment ibd